The Trump administration is cracking open the door to using prescription drugs imported from overseas—ones that have not been approved by the FDA—to combat high drug prices in limited circumstances. The FDA said Thursday that it plans to create a working group to examine how to safely import drugs in a specific situation: when there’s a sharp price increase for an off-patent drug produced by a single manufacturer. (Laurie McGinley, Washington Post)
